Alterity Therapeutics Ltd

Alterity Therapeutics, an Australian biotech focused on Alzheimer’s and age‑related disorder drugs, trades on ASX with a 52‑week low of 0.007 AUD, a negative P/E of –6.45 and a market cap of ~97.9 million AUD.

Alterity Therapeutics: Low‑priced biotech with ambitious Alzheimer’s drug research, yet weak earnings and opaque filings raise investor concerns.

Alterity Therapeutics: Explore its volatile stock, negative P/E and the battle to deliver Alzheimer’s therapies amid financial challenges.

Alterity Therapeutics: Melbourne‑based biotech pushing Alzheimer’s and age‑related disorder drugs, spotlighting Multiple System Atrophy Awareness Month, with volatile stock yet strong investor confidence.